Signos Inc., the company behind the first FDA-cleared, over-the-counter glucose monitoring system for weight management, today announced a $20 million funding round with investment from GV (Google Ventures), Dexcom, and Blue Cross Blue Shield of Alabama. As part of the partnership with Dexcom, Signos will be available for purchase on Stelo.com, Dexcom’s direct-to-consumer CGM website, making it easier for people to find and access the Signos system.
Signos has grown 10-fold over the past six months, driven by increasing consumer demand for more personalized approaches to weight control. GLP-1 medications have brought millions closer to their health goals, and Signos is designed to complement your progress with the kind of biological self-knowledge that makes results maintainable.
The Signos Behavioral AI: The Missing Piece for GLP-1 Users to Track Towards Their Goals
At the center of the Signos platform is an AI engine that scores your health data, including meals and activities, based on how your body actually responds. Signos then does what no scale, macro tracker, or meal plan can: it demonstrates how your body is trending toward your personal goals.
Glucose data from Dexcom’s Stelo glucose biosensor is processed through Signos’ proprietary AI to provide a unique feedback loop tied to each user’s unique metabolic patterns. Users learn which specific foods drive their glucose higher, which meals keep them in range, and how small adjustments accumulate into meaningful, lasting change.
For people who have used GLP-1 medications, that level of insight fills a critical gap. Rather than relying solely on appetite suppression, Signos builds the metabolic self-knowledge that supports weight management over the long term, giving users and their doctors a data-driven foundation to work from, regardless of what else is part of their care plan.
Building Metabolic Self-Knowledge
“The weight management category is being completely reimagined right now, and the approaches that will endure are the ones that combine the best of medication with the best of personalized data,” said Sharam Fouladgar-Mercer, CEO and founder of Signos. “Signos provides the scoring of every meal with AI, delivering a daily weight loss signal, and giving people the kind of real biological insight that helps users make their results last.”
A Strategic Partnership Grounded in CGM and Glucose Biosensing Leadership
Dexcom’s co-investment reflects a shared belief in the expanding role of glucose biosensing beyond diabetes management. Dexcom has defined the standard for glucose biosensing accuracy and accessibility globally. With the Stelo biosensor powering the Signos system, Dexcom’s participation signals strong industry conviction in the future of glucose intelligence for everyday health.
“Signos has developed a system that translates glucose biosensing data into actionable insights for people focused on weight management,” said Jon Coleman, Chief Commercial Officer at Dexcom. “Making Signos available on Stelo.com is a natural next step. It makes a powerful, FDA-cleared technology even more accessible for people who are already looking for smarter ways to manage their weight and health.”
Payer Validation: Blue Cross Blue Shield of Alabama Joins the Round
Blue Cross Blue Shield of Alabama’s participation via 450 Ventures marks a meaningful signal from the payer community. As one of the most respected regional insurers in the country, BCBS Alabama’s investment reflects growing recognition among healthcare payers that metabolic health tools like Signos represent a proactive, cost-effective path to better member outcomes, particularly as GLP-1 medication costs continue to place pressure on payer systems nationwide.
About Signos, Inc.
Launched in 2018, Signos, Inc. is on a mission to eliminate obesity by igniting the metabolic health movement. Powered by a continuous glucose monitor (CGM), the company’s mobile AI-driven system offers personalized insights into how food, movement, sleep, stress, and more affect each unique body. Signos is the only FDA-cleared CGM system for weight management and requires no prescription. For more information, visit signos.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260527908522/en/
Media gallery
